{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:50:22Z","timestamp":1782190222309,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Otsuka Pharmaceutical (Kr)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12883-017-0950-y","type":"journal-article","created":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T09:37:02Z","timestamp":1503999422000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Cilostazol improves endothelial function in acute cerebral ischemia patients: a double-blind placebo controlled trial with flow-mediated dilation technique"],"prefix":"10.1186","volume":"17","author":[{"given":"Seong-Joon","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Soo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mun Hee","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hoon","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Man","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,29]]},"reference":[{"issue":"6","key":"950_CR1","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1474-4422(08)70094-2","volume":"7","author":"Y Huang","year":"2008","unstructured":"Huang Y, Cheng Y, Wu J, Li Y, Xu E, Hong Z, Li Z, Zhang W, Ding M, Gao X, et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. The Lancet Neurology. 2008;7(6):494\u20139.","journal-title":"The Lancet Neurology"},{"issue":"5","key":"950_CR2","first-page":"563","volume":"37","author":"Y Ikeda","year":"1987","unstructured":"Ikeda Y, Kikuchi M, Murakami H, Satoh K, Murata M, Watanabe K, Ando Y. Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study. Arzneimittelforschung. 1987;37(5):563\u20136.","journal-title":"Arzneimittelforschung"},{"issue":"5","key":"950_CR3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1159\/000138400","volume":"36","author":"T Tanaka","year":"1988","unstructured":"Tanaka T, Ishikawa T, Hagiwara M, Onoda K, Itoh H, Hidaka H. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology. 1988;36(5):313\u201320.","journal-title":"Pharmacology"},{"issue":"1","key":"950_CR4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0168-8227(00)00235-7","volume":"52","author":"CW Ahn","year":"2001","unstructured":"Ahn CW, Lee HC, Park SW, Song YD, Huh KB, Oh SJ, Kim YS, Choi YK, Kim JM, Lee TH. Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2001;52(1):45\u201353.","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"950_CR5","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0002-9149(00)01001-8","volume":"86","author":"SW Park","year":"2000","unstructured":"Park SW, Lee CW, Kim HS, Lee NH, Nah DY, Hong MK, Kim JJ, Park SJ. Effects of cilostazol on angiographic restenosis after coronary stent placement. Am J Cardiol. 2000;86(5):499\u2013503.","journal-title":"Am J Cardiol"},{"issue":"4","key":"950_CR6","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1161\/01.STR.0000157667.06542.b7","volume":"36","author":"SU Kwon","year":"2005","unstructured":"Kwon SU, Cho YJ, Koo JS, Bae HJ, Lee YS, Hong KS, Lee JH, Kim JS. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke. 2005;36(4):782\u20136.","journal-title":"Stroke"},{"issue":"6","key":"950_CR7","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/00005344-199212000-00009","volume":"20","author":"S Takahashi","year":"1992","unstructured":"Takahashi S, Oida K, Fujiwara R, Maeda H, Hayashi S, Takai H, Tamai T, Nakai T, Miyabo S. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol. 1992;20(6):900\u20136.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"950_CR8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.atherosclerosis.2003.08.017","volume":"171","author":"T Wang","year":"2003","unstructured":"Wang T, Elam MB, Forbes WP, Zhong J, Nakajima K. Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication. Atherosclerosis. 2003;171(2):337\u201342.","journal-title":"Atherosclerosis"},{"issue":"8","key":"950_CR9","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/01.CIR.0000117403.64398.53","volume":"109","author":"HK Shin","year":"2004","unstructured":"Shin HK, Kim YK, Kim KY, Lee JH, Hong KW. Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Circulation. 2004;109(8):1022\u20138.","journal-title":"Circulation"},{"issue":"8828","key":"950_CR10","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/0140-6736(92)93147-F","volume":"340","author":"DS Celermajer","year":"1992","unstructured":"Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340(8828):1111\u20135.","journal-title":"Lancet"},{"issue":"6423","key":"950_CR11","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/362801a0","volume":"362","author":"R Ross","year":"1993","unstructured":"Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362(6423):801\u20139.","journal-title":"Nature"},{"issue":"10","key":"950_CR12","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/CIRCULATIONAHA.106.652859","volume":"115","author":"JE Deanfield","year":"2007","unstructured":"Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007;115(10):1285\u201395.","journal-title":"Circulation"},{"key":"950_CR13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3389\/fimmu.2013.00111","volume":"4","author":"W Durante","year":"2013","unstructured":"Durante W. Role of arginase in vessel wall remodeling. Front Immunol. 2013;4:111.","journal-title":"Front Immunol"},{"issue":"23","key":"950_CR14","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1161\/CIRCULATIONAHA.109.892414","volume":"121","author":"N Katakami","year":"2010","unstructured":"Katakami N, Kim YS, Kawamori R, Yamasaki Y. The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the diabetic atherosclerosis prevention by Cilostazol (DAPC) study: a randomized trial. Circulation. 2010;121(23):2584\u201391.","journal-title":"Circulation"},{"issue":"3","key":"950_CR15","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/jcu.21972","volume":"41","author":"DH Shin","year":"2013","unstructured":"Shin DH, Lee JS, Hong JM, Kim SY. Cross-section imaging with M-mode as an alternative method for the measurement of brachial artery flow-mediated vasodilation. Journal of clinical ultrasound : JCU. 2013;41(3):158\u201363.","journal-title":"Journal of clinical ultrasound : JCU"},{"issue":"3","key":"950_CR16","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/STR.0b013e318284056a","volume":"44","author":"EC Jauch","year":"2013","unstructured":"Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2013;44(3):870\u2013947.","journal-title":"Stroke"},{"issue":"1","key":"950_CR17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000327036","volume":"32","author":"YS Lee","year":"2011","unstructured":"Lee YS, Bae HJ, Kang DW, Lee SH, Yu K, Park JM, Cho YJ, Hong KS, Kim DE, Kwon SU, et al. Cilostazol in acute ischemic stroke treatment (CAIST trial): a randomized double-blind non-inferiority trial. Cerebrovasc Dis. 2011;32(1):65\u201371.","journal-title":"Cerebrovasc Dis"},{"key":"950_CR18","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.brainres.2008.01.103","volume":"1203","author":"Y Fujita","year":"2008","unstructured":"Fujita Y, Lin JX, Takahashi R, Tomimoto H. Cilostazol alleviates cerebral small-vessel pathology and white-matter lesions in stroke-prone spontaneously hypertensive rats. Brain Res. 2008;1203:170\u20136.","journal-title":"Brain Res"},{"issue":"2","key":"950_CR19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.5551\/jat.10.93","volume":"10","author":"K Oida","year":"2003","unstructured":"Oida K, Ebata K, Kanehara H, Suzuki J, Miyamori I. Effect of cilostazol on impaired vasodilatory response of the brachial artery to ischemia in smokers. J Atheroscler Thromb. 2003;10(2):93\u20138.","journal-title":"J Atheroscler Thromb"},{"issue":"1","key":"950_CR20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4250\/jcu.2011.19.1.21","volume":"19","author":"KS Kim","year":"2011","unstructured":"Kim KS, Park HS, Jung IS, Park JH, Ahn KT, Jin SA, Park YK, Kim JH, Lee JH, Choi SW, et al. Endothelial dysfunction in the smokers can be improved with oral cilostazol treatment. Journal of cardiovascular ultrasound. 2011;19(1):21\u20135.","journal-title":"Journal of cardiovascular ultrasound"},{"issue":"5","key":"950_CR21","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s00380-012-0282-1","volume":"28","author":"IS Jeong","year":"2013","unstructured":"Jeong IS, Park JH, Jin SA, Kim JH, Lee JH, Choi SW, Jeong JO, Seong IW. Oral sarpogrelate can improve endothelial dysfunction as effectively as oral cilostazol, with fewer headaches, in active young male smokers. Heart Vessel. 2013;28(5):578\u201382.","journal-title":"Heart Vessel"},{"issue":"1\u20132","key":"950_CR22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0014-2999(96)00551-1","volume":"314","author":"U Ikeda","year":"1996","unstructured":"Ikeda U, Ikeda M, Kano S, Kanbe T, Shimada K. Effect of cilostazol, a cAMP phosphodiesterase inhibitor, on nitric oxide production by vascular smooth muscle cells. Eur J Pharmacol. 1996;314(1\u20132):197\u2013202.","journal-title":"Eur J Pharmacol"},{"issue":"15","key":"950_CR23","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S0024-3205(01)01258-9","volume":"69","author":"T Nakamura","year":"2001","unstructured":"Nakamura T, Houchi H, Minami A, Sakamoto S, Tsuchiya K, Niwa Y, Minakuchi K, Nakaya Y. Endothelium-dependent relaxation by cilostazol, a phosphodiesteras III inhibitor, on rat thoracic aorta. Life Sci. 2001;69(15):1709\u201315.","journal-title":"Life Sci"},{"issue":"11","key":"950_CR24","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.amjcard.2003.08.013","volume":"92","author":"S Rajagopalan","year":"2003","unstructured":"Rajagopalan S, Pfenninger D, Somers E, Kehrer C, Chakrabarti A, Mukherjee D, Brook R, Kaplan MJ. Effects of cilostazol in patients with Raynaud's syndrome. Am J Cardiol. 2003;92(11):1310\u20135.","journal-title":"Am J Cardiol"},{"issue":"10","key":"950_CR25","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.5551\/jat.32912","volume":"23","author":"H Mori","year":"2016","unstructured":"Mori H, Maeda A, Wakabayashi K, Sato T, Sasai M, Tashiro K, Iso Y, Ebato M, Suzuki H. The effect of Cilostazol on endothelial function as assessed by flow-mediated dilation in patients with coronary artery disease. J Atheroscler Thromb. 2016;23(10):1168\u201377.","journal-title":"J Atheroscler Thromb"},{"issue":"1","key":"950_CR26","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1172\/JCI114688","volume":"86","author":"MA Creager","year":"1990","unstructured":"Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, Dzau VJ. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest. 1990;86(1):228\u201334.","journal-title":"J Clin Invest"},{"issue":"2 Pt 2","key":"950_CR27","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1161\/01.HYP.37.2.444","volume":"37","author":"E Bragulat","year":"2001","unstructured":"Bragulat E, de la Sierra A, Antonio MT, Coca A. Endothelial dysfunction in salt-sensitive essential hypertension. Hypertension. 2001;37(2 Pt 2):444\u20138.","journal-title":"Hypertension"},{"issue":"1","key":"950_CR28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0021-9150(98)00170-1","volume":"141","author":"GF Watts","year":"1998","unstructured":"Watts GF, Playford DA. Dyslipoproteinaemia and hyperoxidative stress in the pathogenesis of endothelial dysfunction in non-insulin dependent diabetes mellitus: an hypothesis. Atherosclerosis. 1998;141(1):17\u201330.","journal-title":"Atherosclerosis"},{"issue":"21 Suppl 1","key":"950_CR29","first-page":"II27","volume":"109","author":"U Landmesser","year":"2004","unstructured":"Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation. 2004;109(21 Suppl 1):II27\u201333.","journal-title":"Circulation"},{"issue":"6 Suppl 2","key":"950_CR30","doi-asserted-by":"crossref","first-page":"1650S","DOI":"10.1093\/jn\/137.6.1650S","volume":"137","author":"RH Boger","year":"2007","unstructured":"Boger RH. The pharmacodynamics of L-arginine. J Nutr. 2007;137(6 Suppl 2):1650S\u20135S.","journal-title":"J Nutr"},{"issue":"3","key":"950_CR31","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jacc.2005.04.040","volume":"46","author":"F Perticone","year":"2005","unstructured":"Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, Tripepi G, Sesti G, Zoccali C. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol. 2005;46(3):518\u201323.","journal-title":"J Am Coll Cardiol"},{"issue":"9299","key":"950_CR32","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(01)07217-8","volume":"358","author":"C Zoccali","year":"2001","unstructured":"Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001;358(9299):2113\u20137.","journal-title":"Lancet"},{"issue":"18","key":"950_CR33","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1161\/01.CIR.98.18.1842","volume":"98","author":"RH Boger","year":"1998","unstructured":"Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998;98(18):1842\u20137.","journal-title":"Circulation"},{"issue":"2","key":"950_CR34","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.atherosclerosis.2006.01.022","volume":"189","author":"A Hashimoto","year":"2006","unstructured":"Hashimoto A, Miyakoda G, Hirose Y, Mori T. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP\/protein kinase A- and phosphatidylinositol 3-kinase\/Akt-dependent mechanism. Atherosclerosis. 2006;189(2):350\u20137.","journal-title":"Atherosclerosis"},{"issue":"2","key":"950_CR35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/1358863x03vm474oa","volume":"8","author":"SM Bode-Boger","year":"2003","unstructured":"Bode-Boger SM, Muke J, Surdacki A, Brabant G, Boger RH, Frolich JC. Oral L-arginine improves endothelial function in healthy individuals older than 70 years. Vasc Med. 2003;8(2):77\u201381.","journal-title":"Vasc Med"},{"issue":"3","key":"950_CR36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.pharmthera.2007.03.002","volume":"114","author":"SM Bode-Boger","year":"2007","unstructured":"Bode-Boger SM, Scalera F, Ignarro LJ. The L-arginine paradox: importance of the L-arginine\/asymmetrical dimethylarginine ratio. Pharmacol Ther. 2007;114(3):295\u2013306.","journal-title":"Pharmacol Ther"},{"issue":"6","key":"950_CR37","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/clc.4960250610","volume":"25","author":"M Frick","year":"2002","unstructured":"Frick M, Alber HF, Hugel H, Schwarzacher SP, Pachinger O, Weidinger F. Short- and long-term changes of flow-mediated vasodilation in patients under statin therapy. Clin Cardiol. 2002;25(6):291\u20134.","journal-title":"Clin Cardiol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-017-0950-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T18:00:39Z","timestamp":1570039239000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-017-0950-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,29]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["950"],"URL":"https:\/\/doi.org\/10.1186\/s12883-017-0950-y","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,29]]},"article-number":"169"}}